BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2009

View Archived Issues

Ingested hrIFN-alpha preserves beta-cell function in diabetic children

Read More

Positive results for peginterferon alfa-2b or alfa-2a in combination with ribavirin in treating HCV

Read More

Conjugates of HMG-CoA reductase and renin inhibitors in development at LEK

Read More

Postlicense safety data on Gardasil largely consistent with prelicense study data

Read More

Merck KGaA claims novel serine/threonine-protein kinase inhibitors

Read More

NasalFent filed in U.S. for breakthrough cancer pain

Read More

FDA sets date for review of pixantrone NDA

Read More

Recent study indicates that AL-1 may be a possible therapy for influenza

Read More

Biotec Pharmacon completes patient inclusion in phase III study for oral mucositis

Read More

AstraZeneca discloses novel PI3Kbeta inhibitor for use in antithrombotic therapy

Read More

Schering-Plough launches Remeron for depression in Japan

Read More

Novel dihydrofolate reductase inhibitors described by Universidad de Murcia

Read More

New sensitive cardiac troponin assays may improve diagnosis of MI and ACS

Read More

EpiCept claims caspase activators and apoptosis inducers as oncolytics

Read More

Rohto discovers alpha-MSH inhibitors for the treatment of dermatological disorders

Read More

Ipsen and Debiopharm enter worldwide license agreement for Debio-0931

Read More

PAION completes patient recruitment for phase IIa study of CNS-7056

Read More

U.K. launch for Regurin XL for overactive bladder

Read More

Sinovac Biotech's H1N1 vaccine approved in China

Read More

Sucampo withdraws European MAA for lubiprostone for idiopathic constipation

Read More

Biogen Idec announces proposal to acquire Facet Biotech

Read More

FDA approves Zevalin expanded label in follicular non-Hodgkin's lymphoma

Read More

Independent research confirms superiority of midkine combined with conventional cancer markers

Read More

Neublastin enters into phase I clinical development for neuropathic pain

Read More

Glenmark Pharmaceuticals describes vanilloid receptor 1 modulators for the treatment of pain

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 8, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • China compass

    ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

    BioWorld
    If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • Woman taking medication for mental illness

    Autobahn on the fast track with bipolar thyroid agonist

    BioWorld
    Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing